Wells Fargo & Company MN reduced its position in Masimo Co. (NASDAQ:MASI) by 10.3% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 281,643 shares of the medical equipment provider’s stock after selling 32,355 shares during the period. Wells Fargo & Company MN owned approximately 0.54% of Masimo worth $27,502,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of MASI. Mount Yale Investment Advisors LLC purchased a new position in Masimo in the 1st quarter valued at about $101,000. Cerebellum GP LLC purchased a new position in Masimo in the 2nd quarter valued at about $173,000. Campbell & CO Investment Adviser LLC purchased a new position in Masimo in the 1st quarter valued at about $202,000. Matisse Capital purchased a new position in Masimo in the 2nd quarter valued at about $202,000. Finally, Neuberger Berman Group LLC purchased a new position in Masimo in the 1st quarter valued at about $203,000. 87.40% of the stock is owned by institutional investors.

Shares of MASI stock opened at $117.30 on Friday. Masimo Co. has a one year low of $80.69 and a one year high of $118.09. The stock has a market cap of $6.02 billion, a PE ratio of 40.11, a P/E/G ratio of 2.72 and a beta of 0.89.

Masimo (NASDAQ:MASI) last issued its quarterly earnings results on Wednesday, August 1st. The medical equipment provider reported $0.73 EPS for the quarter, topping the consensus estimate of $0.71 by $0.02. Masimo had a net margin of 15.30% and a return on equity of 21.49%. The business had revenue of $211.62 million for the quarter, compared to analysts’ expectations of $207.85 million. During the same quarter last year, the company posted $0.83 earnings per share. The company’s quarterly revenue was up 10.0% compared to the same quarter last year. research analysts forecast that Masimo Co. will post 2.9 EPS for the current fiscal year.

In other news, Director Sanford Fitch sold 2,000 shares of the stock in a transaction dated Friday, June 1st. The shares were sold at an average price of $100.21, for a total transaction of $200,420.00. Following the transaction, the director now owns 63,832 shares of the company’s stock, valued at $6,396,604.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Steven Barker sold 10,000 shares of the stock in a transaction dated Wednesday, May 30th. The stock was sold at an average price of $100.00, for a total transaction of $1,000,000.00. Following the transaction, the director now directly owns 73,249 shares in the company, valued at approximately $7,324,900. The disclosure for this sale can be found here. Insiders have sold 118,347 shares of company stock worth $12,746,589 in the last ninety days. Corporate insiders own 12.60% of the company’s stock.

A number of equities analysts have weighed in on MASI shares. Zacks Investment Research cut shares of Masimo from a “buy” rating to a “hold” rating in a research report on Tuesday, May 1st. Piper Jaffray Companies upped their price objective on shares of Masimo to $94.00 and gave the company a “neutral” rating in a research report on Wednesday, May 2nd. BTIG Research reissued a “buy” rating and issued a $100.00 price objective on shares of Masimo in a research report on Thursday, May 3rd. ValuEngine raised shares of Masimo from a “hold” rating to a “buy” rating in a research report on Monday, May 7th. Finally, BidaskClub raised shares of Masimo from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 8th. Two research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $102.60.

About Masimo

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Featured Article: Diversification in Your Portfolio

Institutional Ownership by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.